By BriaCell Therapeutics Corp.
Publication Date: 2025-11-20 12:30:00
-
The collaboration leverages Receptor AI’s platform to develop highly selective anti-cancer kinase inhibitor products for BriaPro, a subsidiary of BriaCell
-
The partnership is intended to expand BriaPro’s small molecule pipeline
-
The aim is to accelerate the development of next-generation therapeutics with improved efficacy and safety
PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer treatment, announced that its subsidiary, BriaPro Therapeutics Corp. (“BriaPro”) has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to develop isoform-selective anti-cancer kinase inhibitors for multiple cancer indications.
The collaboration will integrate AI-driven molecular design expertise…
